La NMPA de China aprueba la comercialización de la inyección de plozasiran sódico

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Salud #Farmacéutica #InnovaciónMédica #Triglicéridos #FCS #ArrowheadPharma #NMPA

Sanofi grabs Chinese rights to Arrowhead rare disease drug Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

The importance of #China as a growth market for #pharma multinationals is underlined by the news that #Sanofi has paid $130 million upfront for Chinese rights to an #ArrowheadPharma drug under review for a disease associated with elevated #triglyceridelevels.

pharmaphorum.com/news/sanofi-...

Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three precli | ...

#Sarepta #ArrowheadPharma